original ) (raw )The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up
A. Goldhirsch , Alan Coates
Annals of Oncology, 2009
View PDFchevron_right
Predictors of response to second-line endocrine therapy for breast cancer
Sarah Pinder
Breast Cancer Research and Treatment, 1997
View PDFchevron_right
Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy
Tadahiko Shien
The Breast, 2007
View PDFchevron_right
Endocrine Therapy in Metastatic Breast Cancer
rosalba amodio
Annals of the New York Academy of Sciences, 2009
View PDFchevron_right
Assessment of response to therapy in advanced breast cancer. A project of the Programme on Clinical Oncology of the International Union against Cancer, Geneva, …
Marta Ravinovich
Cancer, 1977
View PDFchevron_right
Breast cancer: are long-term and intermittent endocrine therapies equally effective?
Rebecca Emeny
Journal of Cancer Research and Clinical Oncology, 2020
View PDFchevron_right
Time-varying effect and long-term survival analysis in breast cancer patients treated with neoadjuvant chemotherapy
Jean-Yves Pierga
British Journal of Cancer, 2015
View PDFchevron_right
Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer
Noriyuki Katsumata
British journal of cancer, 2009
View PDFchevron_right
280MO Progression free survival with endocrine therapy, before or after chemotherapy, in patients with hormone receptor-positive/HER2-negative metastatic breast cancer in a large multicenter national observational study
Pauline Corbaux
Annals of Oncology, 2020
View PDFchevron_right
Preoperative chemotherapy and endocrine therapy in patients with breast cancer
A. Hönig
… Breast Cancer, 2004
View PDFchevron_right
Metastatic pattern and response to endocrine therapy in human breast cancer
Carsten Rose
Breast Cancer Research and Treatment, 1986
View PDFchevron_right
Impressive long-term response with chemo-endocrine therapy in a premenopausal patient with metastatic breast cancer
Sara Bravaccini
Medicine, 2020
View PDFchevron_right
Prognostic factors in metastatic breast cancer patients obtaining objective response or disease stabilization after first-line chemotherapy with epirubicin. Evidence for a positive effect of maintenance hormonal therapy on overall survival
Alfredo Berruti
Anticancer research
View PDFchevron_right
Prognostic factors in the treatment of breast carcinoma
Valerijus Ostapenko
View PDFchevron_right
Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease
Giuseppe Viale
Annals of Oncology, 2006
View PDFchevron_right
Evaluation of the ability of the Clinical Treatment Score at 5 years (CTS5) compared to other risk stratification methods to predict the response to an extended endocrine therapy in breast cancer patients
andrea villasco
Breast Cancer
View PDFchevron_right
The sequential use of endocrine treatment for advanced breast cancer: where are we?
M. Gnant
Annals of Oncology, 2012
View PDFchevron_right
Predictive factors involved in determining response to neoadjuvant chemotherapy in breast cancer and impact of response on 5 years disease free survival and overall survival
osama shakeel
European Journal of Cancer, 2020
View PDFchevron_right
Tumour ploidy, response and survival in patients receiving endocrine therapy for advanced breast cancer
Robin Stuart-harris
British journal of cancer, 1985
View PDFchevron_right
P131 The neoadjuvant endocrinetherapy vs chemotherapy in postmenopausal woment with ER-positive breast cancer
Vladimir Semiglazov
The Breast, 2007
View PDFchevron_right
Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2- Metastatic Breast Cancer
Alexander Macalalad
Breast Cancer: Basic and Clinical Research, 2015
View PDFchevron_right
Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials
Jérôme Lemonnier
British Journal of Cancer
View PDFchevron_right
Change in Trend in Various Clinico-Pathological Factors and Treatment Profile of Breast Cancer Patients: a Tertiary Cancer Centre Experience
Pamela Jeyaraj
PubMed, 2016
View PDFchevron_right
Endocrine Factors in the Outcome of Systemic Adjuvant Therapy of Early Breast Cancer
alfredo marinelli
Annals of The New York Academy of Sciences, 1993
View PDFchevron_right
MAINTENANCE HORMONAL TREATMENT IMPROVES PROGRESSION FREE SURVIVAL AFTER A FIRST LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC BREAST CANCER
Christophe Tournigand
International Journal of Medical Sciences, 2000
View PDFchevron_right
Assessment of the efficacy of successive endocrine therapies in hormone receptor–positive and HER2-negative metastatic breast cancer: a real-life multicentre national study
Jean-marc Ferrero
European Journal of Cancer, 2019
View PDFchevron_right
Estrogen receptor status: an important variable in predicting response to endocrine therapy in metastatic breast cancer
Marc Lippman
European Journal of Cancer (1965), 1980
View PDFchevron_right
Changes in and Prognostic Value of Hormone Receptor Status in a Series of Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Jean-Louis Achard
The Oncologist, 2007
View PDFchevron_right
Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients
Jean-Yves Pierga
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2001
View PDFchevron_right